Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

by Emu, Brinda, Luca, Diana, Offutt, Carolyn, Grogan, Jane L, Rojkovich, Bernadette, Williams, Marna B, Tang, Meina T, Xiao, Jim, Lee, June H, Davis, John C
Published 2012